News | Ablation Systems | June 16, 2020

FDA and Health Canada Approve Thermedical’s Degassed Saline to Help Reduce Risk of Stroke

Montreal Heart Institute first to use degassed saline during SERF cardiac ablation procedure

Health Canada and the U.S. Food and Drug Administration (FDA) approved Thermedical’s degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter, currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

June 16, 2020 – The Montreal Heart Institute (MHI) and Thermedical, a developer of thermal-ablation systems to treat ventricular arrhythmias, announced the first ablation performed using the Durablate retractable needle catheter and degassed saline, which together eliminate over 98 percent of the air bubbles that can lead to stroke.

Health Canada and the U.S. Food and Drug Administration (FDA) approved Thermedical’s degassed saline for use with its Saline Enhanced Radiofrequency (SERF) Ablation system and Durablate catheter, currently being studied for the treatment of ventricular tachycardia (VT), a leading cause of sudden cardiac death worldwide.

“Although ventricular arrhythmias cannot always be completely cured, the new SERF irrigated needle ablation technique with degassed saline solution represents a great advance for patients with extensive diseases, and for whom the next treatment options would be a heart transplant or mechanical heart,” said Katia Dyrda, M.D., associate professor of medicine, electrophysiology training program director, Montreal Heart Institute.

“Moreover, this innovative procedure has the power to greatly improve the quality of life for patients, and I am extremely happy to work in a hospital that makes breakthrough treatments like this available to patients,” continued Dyrda.
 
SERF ablation with the Durablate catheter is an effective treatment option for patients with ventricular arrhythmias that are resistant to antiarrhythmic drugs or standard ablation procedures. The reason is that Thermedical’s SERF ablation using degassed saline can reach abnormal muscle fibers deep in the heart wall where standard ablation cannot reach and where life-threatening arrhythmias are often located. In addition, Thermedical’s ablation system with degassed saline reduces air bubble volume generated during VT ablation by greater than 98 percent. Clinical research suggests that air bubbles may contribute to procedure-related strokes. 

Dyrda, who is leading Montreal Heart Institute’s participation in the SERF VT Ablation study, was the second practitioner to perform an ablation using the new technology in Canada, and the first to perform this intervention using degassed saline. To date, 11 patients have benefitted from the SERF ablation procedure at MHI and three were treated with the new degassed saline. In total, there have been 21 patients treated with SERF ablation in Canada, and five treatments also included degassed saline.
 
“We hope to one day eliminate or reduce VT episodes in patients and, as a result, significantly improve their quality of life,” said Michael Curley, Ph.D., FHRS, co-founder and chief executive officer of Thermedical. “We are extremely encouraged by Dr. Dyrda and her success in performing ablation using our technology, and we are honored that she is the first in the world to perform it at MHI using our new degassed saline.

“Further, gas released during any form of ablation therapy is a clinical concern for potential procedural-related stroke,” Curley said. “We believe that the use of degassed saline can similarly reduce the amount of gas produced during other ablation procedures such as ablation for atrial fibrillation. We will work to demonstrate the clinical utility of degassed saline for all forms of ablation therapy, and we hope to show that it has widespread ability to reduce gas generated during ablations.”

For more information: www.thermedical.com

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...